159 filings
Page 4 of 8
8-K
nfonjj0m ohzv
18 Aug 21
AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination
8:53am
8-K
56e4 eei12z
16 Aug 21
AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors
12:00am
8-K
7mo 4zbxw9n
27 Jul 21
AzurRx BioPharma Announces $3.0 Million Bought
5:25pm
8-K
1pg39f22zpp4bixb762x
9 Jul 21
Departure of Directors or Certain Officers
5:09pm
8-K
agtt9p 3g
2 Jul 21
Departure of Directors or Certain Officers
5:06pm
8-K
cxnmd0kw s0po
17 Jun 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:57pm
8-K
rxowadh f3
1 Apr 21
AzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 Clinical Trial Topline Results Conference Call
8:00am
8-K
u39m4pj6y
10 Mar 21
AzurRx BioPharma Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
8:49am
8-K
romszhixtu7 b088tf
25 Feb 21
AzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors
8:17am
8-K
fspxrw2r2ilmb
16 Feb 21
Other Events
8:01am
8-K/A
fy4d02k
13 Jan 21
Financial Statements and Exhibits
5:29pm
8-K
7oekkpmd59pc3
8 Jan 21
Entry into a Material Definitive Agreement
5:01pm
8-K
z1nmjw0
5 Jan 21
Other Events
11:57am
8-K
6lhlp m1g5
4 Jan 21
Agreement expands AzurRx’s pipeline of targeted, non-systemic GI therapies
7:32am
8-K
m6cktjuxj9e dy
7 Dec 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:18am
8-K
ks0g 3km0eu6in4kxjh
17 Nov 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1:53pm
8-K
5306yi pxgjd
14 Sep 20
Submission of Matters to a Vote of Security Holders
9:28am
8-K
umi1k4cy
21 Aug 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:35pm
8-K
nqau0ieh
12 Aug 20
AzurRx BioPharma CEO Issues Clarifying Statement to Shareholders
4:36pm
8-K
jyubw
11 Aug 20
Data from first five patients demonstrate positive results with primary efficacy and secondary safety endpoints achieved
5:22pm